Cantor Fitzgerald Reiterates Buy, $12 PT on Obagi Medical Products
Cantor Fitzgerald reiterates its Buy rating with a $60 PT on Obagi Medical Products (NASDAQ: OMPI) ahead of the company's Q4 release
Cantor Fitzgerald says, "Still expecting solid 4Q:11 performance. We currently estimate 4Q:11 revenues of $31M and earnings of $0.22, which is more bullish than Consensus estimates of $31M and $0.19. Our estimates are slightly above company guidance of $29-31M in revenues and EPS of $0.16-0.19."
OMPI closed at $11.13 a share on Friday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.